AIDS Mortality Drops Dramatically in New York City: 1997 Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

CHICAGO--The drop in AIDS mortality in 1997 in New York City, one of the epicenters of the epidemic in the United States, more than matched the overall US decline in deaths due to AIDS recorded in the first half of last year (48% vs 44%).

CHICAGO--The drop in AIDS mortality in 1997 in New York City, one of the epicenters of the epidemic in the United States, more than matched the overall US decline in deaths due to AIDS recorded in the first half of last year (48% vs 44%).

Dr. Kevin DeCock of the Centers for Disease Control and Prevention, and Dr. Mary Ann Chiasson, of the New York City Department of Health, reported the figures at a press conference at the Fifth Conference on Retroviruses and Opportunistic Infections. "We can’t say that the end of the epidemic is in sight, but it certainly is the beginning of a new era," Dr. DeCock said. "The challenge now is to improve prevention efforts."

The CDC statistics show 12,040 US AIDS deaths in the first half of 1997, compared with 21,460 in the first half of 1996. In New York City, the data have been calculated for the entire year of 1997, and show that the benefit cuts across all groups, with women and African-Americans showing substantial decreases.

Dr. Chiasson reported that about 2,600 people in New York City died of AIDS in 1997, compared with about 5,000 in 1996. The rate of decline was 50% for men and 46% for women.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content